Ustekinuma b for Crohn's Disease: Two-Year Results of the Initiative on Crohn and Colitis (ICC) Registry, a Nationwide Prospective Observational Cohort Study

T. Straatmijer*, V.B.C. Biemans, F. Hoentjen, N.K.H. de Boer, A.G.L. Bodelier, G. Dijkstra, W.A. van Dop, J.J.L. Haans, J.M. Jansen, P.W.J. Maljaars, S. van der Marel, B. Oldenburg, C.Y. Ponsioen, M.C. Visschedijk, A.C. de Vries, R.L. West, C.J. van der Woude, M. Pierik, M. Duijvestein, A.E. van der Meulen-de Jong

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

4 Citations (Web of Science)
Original languageEnglish
Pages (from-to)1920-1930
Number of pages11
JournalJournal of Crohn's & Colitis
Volume15
Issue number11
DOIs
Publication statusPublished - 1 Nov 2021

Keywords

  • Ustekinumab
  • Crohn's disease
  • real-world
  • ICC Registry
  • INFLAMMATORY-BOWEL-DISEASE
  • REAL-WORLD EXPERIENCE
  • SUBCUTANEOUS USTEKINUMAB
  • MAINTENANCE THERAPY
  • MULTICENTER
  • VEDOLIZUMAB
  • OUTCOMES
  • SAFETY

Cite this